ArticleBMJ open2026
Relationship between the urinary albumin-to-creatinine ratio and cardiovascular adverse outcomes in the Beijing community population: a prospective cohort study.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the correlation between the urinary albumin-to-creatinine ratio (UACR) and adverse cardiovascular outcomes in the Beijing community population.
designProspective cohort study.
settingBeijing, China, from May 2014 to December 2021.
participantsRecruited from a survey conducted as part of an ongoing atherosclerosis cohort study in the communities of Gucheng and Pingguoyuan, Shijingshan District in Beijing, China. Excluded participants who already had a history of stroke or myocardial infarction at baseline. Finally, 3627 eligible participants were included in this analysis. EXPOSURE: The participants were divided into three groups on the basis of baseline UACR: the normal group (UACR<30 mg/g), the microalbuminuria group (30 mg/g≤UACR<300 mg/g) and the dominant proteinuria group (UACR≥300 mg/g). PRIMARY AND SECONDARY OUTCOME MEASURES: The primary endpoint was a composite endpoint (major adverse cardiovascular event, MACE) of cardiovascular death, first acute myocardial infarction or first stroke, whereas secondary endpoints included cardiovascular death, first acute myocardial infarction, first stroke or all-cause death.
resultsThe study included 3627 participants. According to the multivariable Cox model, compared with those in the normal group, the risks of MACE (HR=1.47; 95% CI 1.06 to 2.06; p=0.023), cardiovascular death (HR=3.03; 95% CI 1.56 to 5.88; p=0.001) and all-cause mortality (HR=1.91; 95% CI 1.23 to 2.97; p=0.004) were significantly greater in the microalbuminuria group. The risk of MACE (HR=3.65; 95% CI 2.14 to 6.23; p<0.001), cardiovascular death (HR=7.91; 95% CI 2.92 to 21.43; p<0.001), stroke (HR=2.57; 95% CI 1.30 to 5.08; p=0.007) and all-cause death (HR=3.59; 95% CI 1.63 to 7.89; p=0.001) in the group with dominant proteinuria was significantly greater than that in the normal group. The absolute risk differences (per 1000 person-years) for MACE were 14.86 (95% CI 7.20 to 22.51) in the microalbuminuria group and 64.85 (95% CI 26.76 to 102.94) in the dominant proteinuria group, compared with the normal group (incidence rates: 25.24 and 75.23 vs 10.38, respectively). In populations with a UACR less than 30 mg/g, there was a significant increase in the risk of MACE as the UACR increased (HR=1.02; 95% CI 1.00 to 1.04; p=0.036).
conclusionsThis study indicates that an elevated UACR is a significant risk factor for adverse cardiovascular outcomes within the community population. This association remains consistent in individuals with low-grade albuminuria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.